Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and …
Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a
cornerstone treatment for type 2 diabetes mellitus (T2DM). The aim of the present meta …
cornerstone treatment for type 2 diabetes mellitus (T2DM). The aim of the present meta …
Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis
S Hu, X Su, G Fan - Diabetology & Metabolic Syndrome, 2023 - Springer
Objectives To update and assess the efficacy and tolerability of once weekly subcutaneous
semaglutide in patients with type 2 diabetes (T2D). Materials and methods PubMed, Science …
semaglutide in patients with type 2 diabetes (T2D). Materials and methods PubMed, Science …
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the …
Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: the PIONEER 1 randomized clinical trial as an example
Regulatory guidelines describe the use of estimands in designing and conducting clinical
trials. Estimands ensure alignment of the objectives with the design, conduct and analysis of …
trials. Estimands ensure alignment of the objectives with the design, conduct and analysis of …
Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
OF Onoviran, D Li, S Toombs Smith… - … advances in chronic …, 2019 - journals.sagepub.com
Elderly patients with diabetes are at high risk of polypharmacy because of multiple
coexisting diseases and syndromes. Polypharmacy increases the risk of drug–drug and …
coexisting diseases and syndromes. Polypharmacy increases the risk of drug–drug and …
The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review
Purpose The present study aimed to systematically collect and synthesize available cost-
effectiveness studies of semaglutide in patients with obesity or overweight in comparison …
effectiveness studies of semaglutide in patients with obesity or overweight in comparison …
[HTML][HTML] Obesity management for the treatment of type 2 diabetes
Interventions to address obesity are recommended as treatments for type 2 diabetes. In this
article, nationally representative data are used to describe behavioral, pharmacologic, and …
article, nationally representative data are used to describe behavioral, pharmacologic, and …
[HTML][HTML] Weekly semaglutide vs. liraglutide efficacy profile: a network meta-analysis
HA Alsugair, IF Alshugair, TJ Alharbi, AM Bin Rsheed… - Healthcare, 2021 - mdpi.com
Introduction: Glucagon-like peptide 1 receptor agonist (GLP-1 RA) is a class of
hypoglycemic medications. Semaglutide once-weekly (QW) and liraglutide once-daily (OD) …
hypoglycemic medications. Semaglutide once-weekly (QW) and liraglutide once-daily (OD) …
Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis
BM Mishriky, JR Powell, JA Wittwer… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aims While recent cardiovascular safety trials (CVST) concerning newer diabetes
medications included mostly white participants, results are being generalized to all races in …
medications included mostly white participants, results are being generalized to all races in …
The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review
Introduction: As a novel glucagon-like peptide-1receptor agonist (GLP-1 RA) for type 2
diabetes (T2D) treatment, the economic value of once-weekly semaglutide had been …
diabetes (T2D) treatment, the economic value of once-weekly semaglutide had been …